Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Tenax Therapeutics, Inc.NASDAQ: TENX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 47.6% from a year ago
Other current liabilities stood at $490K at the end of Q1 FY2026, up 47.6% from a year earlier and down 45.4% from the prior quarter. Over 3 fiscal years it compounded at +54.1% a year.
Context
- Other current liabilities amounted to 0.4% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +47.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 898K USD
- Year-over-year change
- -32.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 898K | -32.8% |
| FY2024 | 2024-12-31 | 1.34M | +464.0% |
| FY2023 | 2023-12-31 | 236.88K | -3.5% |
| FY2022 | 2022-12-31 | 245.39K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 other current liabilities of $490K is the 6th highest of the 7 companies compared; the peer median is $2.48M.
- Its year-over-year change of +47.6% is the 3rd highest of 6, against a peer median of +4.6%.
- Other current liabilities amounts to 0.4% of total assets for TENX, versus a peer median of 2.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +450133.7% | — | 4.2% | |
| Mar 2026 | $11.39M | -11.1% | +95.4% | 29.4% | |
| Mar 2026 | $3.78M | +4.6% | +8.2% | 5.9% | |
| Mar 2026 | $1.18M | +219.8% | +717.7% | 1.3% | |
| Mar 2026 | $589K | -47.6% | +1.2% | 0.4% | |
| Mar 2026 | $490K | +47.6% | +54.1% | 0.4% | |
| Jun 2026 | $0 | — | -42.4% | 0.0% | |
| Peer median (excluding TENX) | $2.48M | +4.6% | +8.2% | 2.8% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.